Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00399711 · ClinicalTrials.gov registry record · Phase 3
Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 560
- Enrollment target
NCT00399711: Completed Phase 3 study, sponsored by Novo Nordisk A/S.
NCT00399711 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 560 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00399711, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 560 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). This trial compares the changes in HbA1c after 26 weeks of repaglinide and metformin fixed dose combination tablet given as twice daily versus three times daily regimens or versus twice daily rosiglitazone and metformin fixed dose combination tablet in subjects with type 2 diabetes currently on monotherapy.
Interventions
- DRUG repaglinide and metformin combination tablet
- DRUG rosiglitazone and metformin combination tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
What the finished NCT00399711 record still lists
NCT00399711 is an interventional study that assigns participants to a tested intervention. The registered 560 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% lower).
The record links to 0 conditions, and to 2 interventions - of which repaglinide and metformin combination tablet is the first listed.
NCT00399711 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00399711 about?
NCT00399711 is a clinical study titled "Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes". This trial is conducted in the United States of America (USA). This trial compares the changes in HbA1c after 26 weeks of repaglinide and metformin fixed dose combination tablet given as twice daily versus three times daily regimens or versus twice daily rosiglitazone and metformin fixed dose combin...
What is the current status of trial NCT00399711?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 560 participants. The study started on 2006-11. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00399711?
The interventions under investigation include: repaglinide and metformin combination tablet (DRUG), rosiglitazone and metformin combination tablet (DRUG).
Who is sponsoring clinical trial NCT00399711?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00399711's enrollment target sits among peer trials
560 671st of 2000 higher than 1,328 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04661358 · 560 participants · Phase 3
Fenofibrate for Prevention of DR Worsening
- NCT05473871 · 560 participants · NA
Enhancing Capacity in Churches to Implement PA Programs
- NCT06001541 · 560 participants · NA
Web-based Program to Improve Self-management Among Veterans-caregiver Dyads
- NCT06246916 · 560 participants · Phase 3
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia